89Zr-anti-LTA mAb (Humabs BioMed/MedImmune/IRB/Johns Hopkins Univ)

N/A

Report date: 2025/10/28 17:33:48

Base Information

Drug Name89Zr-anti-LTA mAb (Humabs BioMed/MedImmune/IRB/Johns Hopkins Univ)
Drug Alias NameN/A
ClassificationRadiation-emitting productsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionBacterial cell wall synthesis inhibitors
TargetsUpdating
Therapy Area/IndicationsBone and Joint Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHumabs Biomed Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHumabs Biomed SaJohns Hopkins UniversityMedimmune Llc +[4] 
Active IndicationsN/A
Inactive IndicationsBone and Joint Infections

Other Information

ATC CodeN/A
Related LinksN/A